Could a JAK inhibitor tame chronic hives? new trial aims to find out
NCT ID NCT06795373
First seen Dec 10, 2025 · Last updated Apr 24, 2026 · Updated 22 times
Summary
This study tested whether the drug ritlecitinib can safely control chronic spontaneous urticaria (CSU) — hives and itching lasting over six weeks. The trial planned to enroll adults aged 18–65 who would take the drug daily for 12 weeks and track their symptoms. However, the study was withdrawn before any participants enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.